Interim phase 3 APeX-P data presented at AAAAI 2026 show sustained 48-week reductions in moderate and severe HAE attacks with oral berotralstat in children aged 2–11 years.
Jolanta Bernatoniene, PhD
Advertisement
Articles by Jolanta Bernatoniene, PhD
Berotralstat becomes the first once-daily oral prophylactic option for long-term prevention of hereditary angioedema in children aged 2–11 years.
Jolanta Bernatoniene, PhD, discussed positive results from the APeX-P study of oral berotralstat in children with hereditary angioedema.
Advertisement
Latest Updated Articles
Berotralstat: First Oral HAE Prophylaxis Approved for Ages 2–11January 15th 2026
Oral Berotralstat May Reduce Symptom Burden in Pediatric HAEMarch 18th 2025
Advertisement
Advertisement
Trending on HCPLive
1
FDA Grants Full Approval to Iptacopan (Fabhalta) in IgAN
2
Enlicitide Receives FDA Approval for Hypercholesterolemia Following CORALreef Trials
3
Why Aldosterone Has Become a Key Target in CKD Care, With Marc Richards, MD
4
COMP360 Psilocybin for TRD: What to Know Before a Possible 2027 Launch
5